食管疾病2026，Vol.8Issue(1)：28-32,5.DOI:10.15926/j.cnki.issn2096-7381.2026.01.005
信迪利单抗联合TP化疗对晚期食管癌患者PD-1、PD-L1及肿瘤标志物水平的影响
Effects of Sindilizumab Combined with TP Chemotherapy on Levels of PD-1,PD-L1 and Tumor Markers in Patients with Advanced Esophageal Cancer
王兴旺 1张冰雁 1冯娟娟 1李波 1靳子祺1
作者信息
- 1. 鹤壁市人民医院,河南 鹤壁,458030
- 折叠
摘要
Abstract
Objective To investigate the effect of sindelizumab combined with paclitaxel-cisplatin(TP)chemotherapy in advanced esophageal cancer.Methods 80 patients with advanced esophageal cancer admitted to Hebi People's Hospital from June 2022 to December 2023 were divided randomly into control group(only received TP chemotherapy)and observation group(received Sindilumab combined with TP chemotherapy on the basis of control group),with 40 cases in each.The clinical efficacy,programmed death-1(PD-1)and programmed death-ligand 1(PD-L1)in blood levels,serum tumor marker levels,incidence of adverse reactions and 1 a survival rate were compared between the two groups.Results After treatment,the levels of PD-1,PD-L1 and tumor markers in both groups decreased,and the levels were lower in observation group than those in control group(P＜0.05).After treatment,the total effective rate of the observation group was 87.5%,and the 1-year survival rate was 32.50%,which were significantly higher than 67.50%and 12.50%ofthe control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P＞0.05).The survival curves of the two groups were drawn by Kaplan-Meier method.The 1-year survival rate of the observation group was higher than that of the control group,and the difference was statistically significant(Log-rank χ2=6.901,P=0.009).Conclusion Sindilizumab combined with TP chemotherapy is effective in the treatment of advanced esophageal cancer patients,which can effectively reduce the levels of PD-1,PD-L1 and tumor markers,and significantly improve the 1-year survival rate,with certain safety.关键词
信迪利单抗/TP化疗/食管癌/程序性死亡受体 1/程序性死亡受体配体 1Key words
sindilimab/TP chemotherapy/esophageal cancer/programmed death receptor 1/programmed death receptor ligand 1分类
医药卫生引用本文复制引用
王兴旺,张冰雁,冯娟娟,李波,靳子祺..信迪利单抗联合TP化疗对晚期食管癌患者PD-1、PD-L1及肿瘤标志物水平的影响[J].食管疾病,2026,8(1):28-32,5.
